Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource® LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is funded by PER®.

Community Practice Connections™: 1st Annual European Congress on Genitourinary Malignancies™

Release Date: September 29, 2017
Expiration Date: September 29, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 1st Annual European Congress on Genitourinary Malignancies™ features a summary of clinical evidence guiding best practices in the treatment of patients with genitourinary (GU) cancers, including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with GU malignancies. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with renal cell carcinoma, urothelial carcinoma, and prostate cancer.

Acknowledgement of Commercial Support

This activity is funded by PER®.

CME/CE Activity Table of Contents

  • Module 1: Case of Metastatic, Clear-Cell Renal Cell Carcinoma Through Multiple Lines of Therapy
    Bernard Escudier, MD
  • Module 2: Case of Non‒Clear-Cell Renal Cell Carcinoma From the Adjuvant to Metastatic Setting
    Sumanta Kumar Pal, MD
  • Module 3: Case of Intermediate-Risk, Metastatic Renal Cell Carcinoma With Lung Involvement
    Sumanta Kumar Pal, MD
  • Module 4: Case of Metastatic Urothelial Carcinoma After Adjuvant Cisplatin/Gemcitabine
    Sumanta Kumar Pal, MD
  • Module 5: Clinical Update: Metastatic Castration-Sensitive/-Naïve Prostate Cancer
    Prof. Nicholas James
  • Module 6: Case of Metastatic Prostate Cancer With Bone Involvement
    Prof. Dr. med. Silke Gillessen
  • Module 7: Case of Metastatic Prostate Cancer: Biochemical Progression
    Prof. Dr. med. Silke Gillessen

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical, surgical, and radiation oncologists, as well as other healthcare professionals involved in the treatment and management of patients with GU malignancies. .

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe methods to stratify risk and apply tumor information to inform clinical decision making in the management of GU malignancies
  • Summarize clinical trial evidence and recommendations that shape evolving strategies to care for patients with GU malignancies
  • Evaluate recent practice-changing clinical trial data concerning novel compounds or strategies to manage GU malignancies
  • Discuss how emerging clinical concepts and findings in the management of GU malignancies fit into evolving treatment paradigms in the field

Faculty, Staff, and Planners' Disclosures

Faculty

Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Gutave Roussy
Paris, France
 
 

Disclosure: Consultant/Avisory Boards: Pfizer, Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen

Prof. Dr. med., Silke Gillessen
Chair
EORTC GU Group
Medical Oncology/Hemotology
Kantonsspital
St. Gallen, Switzerland

Disclosure: Consultant/Avisory Boards: Advisory Boards (compensated): AAA International, Active Biotech AB IDMC, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Dendreon Corporation, Ferring, GlaxoSmithKline, Innocrin Pharmaceuticals, Janssen-Cilag, MaxiVAX SA, Millennium Pharmaceuticals, Novartis, Pfizer, Orion, Roche, Sanofi Aventis Group; Advisory Boards (uncompensated): Astellas Pharma, Bayer, ESSA Pharma, Nectar, ProteoMediX, Sanofi, Speakers Bureau: Janssen, Novartis (compensated); Amgen, Astellas Pharma, Bayer, Janssen, Sanofi Aventis Group (uncompensated), Other: Patent: Pending patent application for a method for biomarker WO 2009138392 A1

Prof. Nicholas James
Professor of Clinical Oncology
The Medical School University of Birmingham
Birmingham, United Kingdom
 
 

Disclosure: Grant/Research Support: Janssen, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis, Other: Personal Fees: Astellas Pharma, Novartis, Pfizer, Sanofi-Aventis; Non-Financial Support: Astellas Pharma, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis

Sumanta K. Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of hope
Duarte, California, USA

Disclosure: Consultant/Avisory Boards: fizer, Bristol-Myers Squibb, Exelixis, Novartis, Ipsen, GlaxoSmithKline, Astellas Pharma, Medivation, Speakers Bureau: Genentech, Other: Sumanta K. Pal, MD Pfizer, Bristol-Myers Squibb, Exelixis, Novartis, Ipsen, GlaxoSmithKline, Astellas Pharma, Medivation Genentech Travel Support: Bristol-Myers Squibb, Novartis, Merck

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

 

PER Pulse Recap™

PER Pulse Recap (1 of 3)

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr. Pal, during which he discusses his approach toward frontline therapy for a patient with intermediate-risk renal cell carcinoma that involves a 0-cm right renal mass, as well as multiple bone and lung lesions. During his interview, Dr. Pal also reviews the role of cytoreductive nephrectomy in this setting, available clinical trials for this patient, and key takeaways from his presentation at the 1st Annual European Congress on Genitourinary Malignancies™ entitled, “Evolving Therapeutic Strategies in Renal Cell Carcinoma: Neoadjuvant and Adjuvant Approaches.” 


PER Pulse Recap (2 of 3)

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr. Pal about his approach toward frontline therapy for a patient with a pT2N2 M0 urothelial carcinoma (UC), who has developed metastatic disease (nonsymptomatic lung lesions detected by routine follow-up imaging; >1% PD-L1 expression) 6 months after completion of adjuvant cisplatin/gemcitabine. During his interview, Dr. Pal reviews the latest data on immune checkpoint inhibitor therapy for UC in the post-platinum setting, as well as ongoing clinical trials in this area.


PER Pulse Recap (3 of 3)

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Prof. James, during which he answers questions about data recently reported from phase III clinical trials of therapy for metastatic castration-sensitive/-naïve prostate cancer, including the LATITUDE and STAMPEDE trials. Prof. James answers questions about the rationale for and status of the STAMPEDE trial; modern-day prognosis for patients with newly diagnosed, advanced prostate cancer; current standards of care in advanced, hormone-sensitive prostate cancer; prevailing controversies regarding the early management of advanced prostate cancer; as well as use of zoledronic acid and the relevance of failure-free survival in this setting.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By